| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8368468 | Advances in Medical Sciences | 2017 | 6 Pages |
Abstract
Treatment with LDV/SOF ± RBV is an effective and safe option for patients with HCV, including those with advanced liver disease or a history of non-response to PEG-IFN-based therapy.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry, Genetics and Molecular Biology (General)
Authors
Robert Flisiak, Mariusz Åucejko, WÅodzimierz Mazur, Ewa Janczewska, Hanna Berak, Krzysztof Tomasiewicz, Iwona Mozer-Lisewska, Dorota Kozielewicz, Andrzej Gietka, Katarzyna Sikorska, Marta Wawrzynowicz-Syczewska, Krzysztof Nowak,